Amanda Lynam, chief credit strategist at Goldman Sachs, says the scale of investment in artificial intelligence is forcing corporates to increasingly diversify their funding outside the US. She speaks on Bloomberg Television. (Source: Bloomberg)
Amanda Lynam, chief credit strategist at Goldman Sachs, says the scale of investment in artificial intelligence is forcing corporates to increasingly diversify their funding outside the US. She speaks on Bloomberg Television. (Source: Bloomberg)
wildpixel/iStock via Getty Images Liquidia Overview Liquidia's ( LQDA ) first-quarter earnings report looks like everything bulls were hoping for. Yutrepia's net product sales were up 44% sequentially, the business recorded its third consecutive quarter of profitability, and its pipeline is advancing as expected. In my last analysis, in March, I upgraded LQDA to Hold. Although I had been bearish o...
wildpixel/iStock via Getty Images Liquidia Overview Liquidia's ( LQDA ) first-quarter earnings report looks like everything bulls were hoping for. Yutrepia's net product sales were up 44% sequentially, the business recorded its third consecutive quarter of profitability, and its pipeline is advancing as expected. In my last analysis, in March, I upgraded LQDA to Hold. Although I had been bearish on the name in the past (read my January Sell analysis), Yutrepia’s initial commercial numbers demanded a change of heart. While I've become increasingly optimistic on Liquidia's short-term prospects, I’ve remained cautious on the long-term trajectory for multiple reasons. Due to limited product differentiation, I posited that Yutrepia’s market share gains were capped by patient preferences and established players. Moreover, I noted some major competitive risks that are on the horizon, such as United Therapeutics’ ( UTHR ) Tresmi (a soft mist inhaler, planned NDA submission later this year) and Ralinepag (an oral, once-daily prostacyclin, planned NDA submission later this year). And don't forget about Insmed’s ( INSM ) once-daily TPIP (Phase 3). Now, Liquidia does have plans to address, or strengthen, its competitive moat, including a twice-daily nebulizer (arguably a step backward on device convenience vs. DPIs), L606, but I thought that this late-stage prospect offers, at best, only incremental convenience advantages. And L606 also faces less favorable economics than Yutrepia due to royalty obligations. With LQDA up over 20% in intraday trading (at writing) and its market capitalization inching closer to $5 billion, I wanted to do a deep dive on the hidden implications of Liquidia's first-quarter results. Data by YCharts My analysis reveals that Liquidia’s valuation may now imply that the market is becoming too short-sighted. Recent Developments I'm only going to briefly cover the numbers because they're clearly listed there in the earnings report. Liquidia beat consensus ...
(RTTNews) - European stocks traded lower on Tuesday as hopes for a U.S.-Iran peace deal diminished and data showed German inflation increased for the second consecutive month as a result of another rise in energy prices due to the Iran war.
(RTTNews) - European stocks traded lower on Tuesday as hopes for a U.S.-Iran peace deal diminished and data showed German inflation increased for the second consecutive month as a result of another rise in energy prices due to the Iran war.
Maskot/DigitalVision via Getty Images Investment Summary My previous investment thought on Waystar ( WAY ) was a buy rating because there was clear evidence that demand was picking up and that AI wasn’t really a disruption risk that most people thought it to be. After reviewing the latest results, I still give a buy rating. The headline guide change may worry some investors, but I do not think it ...
Maskot/DigitalVision via Getty Images Investment Summary My previous investment thought on Waystar ( WAY ) was a buy rating because there was clear evidence that demand was picking up and that AI wasn’t really a disruption risk that most people thought it to be. After reviewing the latest results, I still give a buy rating. The headline guide change may worry some investors, but I do not think it reflects weaker demand. The pressure came mainly from patient payment solutions, while bookings, win rates, pipeline, and large deal activity all still looked strong. With provider solutions growing faster, margins staying healthy, and AI plus Iodine supporting the broader platform story, I continue to see upside here. Q1 2026 Results Update WAY reported Q1 revenue of $313.9 million, a 22% y/y growth, with subscription revenue being the main driver coming in at $172.2 million, up 38% y/y. Volume-based revenue saw $139.5 million, up 7%. The underlying mix was very positive too. As of Q1 2026, WAY has 1,433 clients contributing >$100,000 in last-twelve-month [LTM] revenue, up 15% y/y, and it has added 42 new clients above that threshold in Q1. This came along with existing customers spending more as net revenue retention was 111%. By segments, provider solutions were the driver there. As a recap, this segment is ~75% of total revenue, and management said provider solutions organically grew at ~2x the rate of patient payment solutions. These drove adj. EBITDA to $135.4 million, up close to 30%, and adj. EBITDA margin to 43%. Also on an adjusted basis, net income saw $81.2 million, or $0.42 per diluted share. The Quarter Was Noisier, but the Core Demand Story Got Stronger I believe the main debate after Q1 should not be whether demand weakened. I really don’t think it did, but I can understand why some investors may think that way. In my view, the noise came from the patient payment solutions segment. For those that missed it, management said that Q1 volume-based trends saw mod...